About
AAPharmaSyn

We are a Science Company. From inception we structured ourselves around our customers and their needs. Throughout the years we focused on improving customer experience and will continue to invest whatever resources required in order to provide exceptional service that always meets and regularly exceeds customer expectations.

banner_iconsbanner_iconsbanner_iconsbanner_icons

AAPharmaSyn celebrates customer centric culture and empowers all employees to enhance customer experience. In engaging AAPharmaSyn our customer can always expect:

card_icons

Impeccable Communication

  • Articulate Dialogue
  • Active Listening
  • Insightful Questions
  • Clear And Concise Written Exchanges
  • Complete Transparency
card_icons

Relentless Execution

  • On Time And On Budget Delivery
  • Strategic Planning With Deliberate And Purposeful Actions
  • Proactive Anticipation And Mitigation Of High-Impact, High-Likelihood Challenges
  • Highly Qualified Personnel
  • Comprehensive Partner Network
card_icons

Unbounded Creativity

  • Proven And Operationalized Methodology For Solving Hard Technical Challenges
  • Extensive Experience To Draw On
  • Well-Developed Ability To Triangulate And Draw Project Relevant Insights
  • Broad Range Of Value-Adding Resources
  • Unparalleled Enthusiasm And Intrinsic Drive To Solve Hard Problems

Company Timeline

Pfizer acquires Parke – Davis company.

2000

Pfizer announces shutting down of Parke – Davis Ann Arbor Facilities. Pfizer research fellows decide to try their hand at entrepreneurship and found AAPharmaSyn.

2001-2006

Bootstrapped, the company recruits former Ann Arbor Pfizer employees and opens its doors for business. Building on the legacy of excellence in synthetic chemistry, AAPharmaSyn finds customers and is profitable within the first year of operations.

2006-2010

AAPharmaSyn moves to a new facility with custom infrastructure to meet the needs of its customers. The company expands its services and hires additional employees. Successful track record of meeting deliverables on time and on schedule allows company to generate strong repeat business.

2011-2020

AAPharmaSyn has been acquired by a strategic investor, marking the beginning of an exciting new chapter for the company. As part of this transition, AAPharmaSyn underwent a comprehensive repositioning to align with its enhanced vision and strategic goals. With a renewed focus on delivering exceptional value, the company committed to strengthening its relationships with its diverse client base, driving innovation, and expanding its capabilities to meet evolving industry demands. This transition underscored a shared commitment to excellence and set the stage for long-term growth and success.

2020-2023

AAPharmaSyn is actively expanding its capabilities through strategic partnership agreements with local businesses that align with its vision of creating a comprehensive, one-stop solution for early-stage pharmaceutical companies. These collaborations are designed to enhance AAPharmaSyn's service offerings, streamline processes, and provide tailored support to emerging pharmaceutical ventures. By leveraging local expertise and fostering synergies, the company is strengthening its position as a trusted partner in the pharmaceutical development ecosystem, committed to driving innovation and supporting the growth of its clients.

2024 -